Venous Thromboembolism (VTE) Prophylaxis for Hospitalized Surgical Pediatric Patients (Age 10-17 years)

Patients 10-17 years old who are expected to have a surgical procedure lasting ≥ 60 minutes

INITIAL ASSESSMENT

RISK STRATIFICATION

HIGH RISK
- Expected altered mobility > 48 hours and ≥ 2 VTE risk factors

Is patient a candidate for pharmacological prophylaxis?

Yes

No

TREATMENT

- Initiate mechanical prophylaxis prior to anesthesia in the OR and continue postoperatively until patient is ambulatory if no contraindications exist
- Consider pharmacological prophylaxis to start 12-24 hours (24-48 hours for neurosurgical cases) postoperatively and continue until patient is ambulatory. Notify anesthesia team as this may affect anesthetic choice.
- Encourage ambulation
- Mitigate risk factors

- Initiate mechanical prophylaxis prior to anesthesia in the OR and continue postoperatively until patient is ambulatory if no contraindications exist
- Encourage ambulation
- Reassess for pharmacologic contraindications daily

MODERATE RISK
- Expected altered mobility > 48 hours and either 0 or 1 VTE risk factor
- Fully ambulatory and ≥ 1 VTE risk factor(s)

- Initiate mechanical prophylaxis prior to anesthesia in the OR and continue postoperatively until patient is ambulatory if no contraindications exist
- Encourage ambulation
- Mitigate risk factors

LOW RISK
- Fully ambulatory with no VTE risk factors

- Initiate mechanical prophylaxis prior to anesthesia in the OR if no contraindications exist
- Encourage ambulation
- Mitigate risk factors

1 Patients < 10 years old do not need VTE prophylaxis perioperatively unless there is known inherited thrombophilia or previous history of DVT; consult Pediatric Hematology in such case
2 See Appendix A for VTE risk factors
3 Altered mobility is defined as a permanent or temporary state in which the child has a limitation in independent, purposeful physical movement of the body or of one or more extremities
4 See Appendix B for contraindications to pharmacological options for VTE prophylaxis
5 See Appendix C for mechanical VTE prophylaxis
6 See Appendix D enoxaparin dosing for VTE prophylaxis in pediatric patients
7 Obtain hematology consult when weighing risk versus benefit in patients at risk of bleeding

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

Copyright 2019 The University of Texas MD Anderson Cancer Center

Department of Clinical Effectiveness V2
Approved by the Executive Committee of the Medical Staff on 06/25/2019
APPENDIX A: VTE Risk Factors

- Active cancer (or suspicion of cancer)
- Blood stream infection
- Central venous catheter (including non-tunneled, tunneled and PICCs)
- Chemotherapy (especially asparaginase, bevacizumab, thalidomide/lenalidomide plus high-dose dexamethasone)
- Exogenous estrogen compounds (contraceptives, hormone replacement, tamoxifen/raloxifene, diethylstilbestrol) within past two months
- History of venous thrombosis
- Hyperosmolar state (serum osmolality > 320 mOsm/kg)
- History of inflammatory diseases (e.g., IBD, SLE)
- Obesity (BMI > 95th percentile for age)
- Orthopedic procedures: hip or knee reconstruction
- History of nephrotic syndrome
- History of familial and/or acquired hypercoagulability
- Major trauma: more than 1 lower extremity long bone fracture, complex pelvic fractures, spinal cord injury
- Major surgery (abdominal, pelvic, orthopedic surgery)
- Erythropoietin stimulating agents in patients undergoing orthopedic surgery
- Immobility
- History of antiphospholipid antibodies
- History of polycythemia
- History of congenital heart disease (non-biologic reconstruction)

APPENDIX B: Contraindications to Pharmacological Options for VTE Prophylaxis

### Absolute Contraindications
- Active bleeding (cerebral, GI, GU) – evidence of or high risk of
- Uncontrolled coagulopathy
- Bleeding disorder (known or tendency)
- Severe thrombocytopenia (platelets < 30 K/microliter)
- Heparin-induced thrombocytopenia (HIT)
- Hypersensitivity to enoxaparin, heparin, pork products, or any component of the formulation
- Epidural or paraspinal hematoma

### Relative Contraindications
- Moderate thrombocytopenia (platelets 30-50 K/microliter)
- Lumbar puncture or epidural catheter removed within past 12 hours
- Intracranial or spinal lesion at high risk of bleeding
- Recent major surgery at high risk of bleeding (e.g., neurosurgical)
- Pelvic fracture within past 48 hours
- Uncontrolled hypertension
- Renal failure

APPENDIX C: Mechanical VTE Prophylaxis

#### Options
- Sequential compression devices (SCDs) (preferred)
- Graduated compression stockings (TED hoses)
- Goal is to use for 18 hours a day

#### Contraindications
- DVT, suspected or existing (can use graduated compression stockings)
- Extremity to be used has acute fracture
- Extremity to be used has PIV access
- Skin conditions affecting extremity (e.g., dermatitis, burn)
- Unable to achieve correct fit due to patient size

APPENDIX D: Enoxaparin Dosing for VTE Prophylaxis in Pediatric Patients

<table>
<thead>
<tr>
<th>Weight</th>
<th>Dosing</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 50 kg</td>
<td>0.5 mg/kg subcutaneously twice daily</td>
</tr>
<tr>
<td>≥ 50 kg</td>
<td>40 mg subcutaneously once daily</td>
</tr>
</tbody>
</table>
SUGGESTED READINGS


Venous Thromboembolism (VTE) Prophylaxis for Hospitalized Surgical Pediatric Patients (Age 10-17 years)

This practice consensus algorithm is based on majority expert opinion of the Pediatric VTE workgroup at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

- Mary Austin, MD (Surgical Oncology)†
- Suzanne Gettys, PharmD (Pharmacy Clinical Programs)
- Lauren Mayon, PA-C (Surgical Oncology)†
- Demetrios Petropoulos, MD (Pediatrics)
- Shehla Razvi, MD (Pediatrics)
- Nidra Rodriguez Cruz, MD (Pediatrics)
- Sonal Yang, PharmD Asterisk

† Core Development Team
* Clinical Effectiveness Development Team

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.